[R&E] The 5,200 Level Swept by Panic Selling and Circuit Breakers; The Prelude to a Semiconductor and Bio Counterattack Amid Energy Volatility

[R&E: Research & Epoch]

This is News Epoch's signature report that analyzes vast market data to provide a perspective on a new era of investment.

Market Overview: Key Indicators and Trends

The previous day, the New York stock market staged a relief rally, succeeding in a technical rebound despite the double whammy of an employment shock and geopolitical risks originating from the Middle East. The S&P 500 and Nasdaq closed up 0.83% and 1.38%, respectively, while the Philadelphia Semiconductor Index surged 3.93% to lead the market rebound. This was the result of the price of $120-threatening WTI (West Texas Intermediate) crude stabilizing downward to the $90-$100 range following the G7's suggestion of releasing strategic petroleum reserves and President Trump's mention of a possible early end to the war.

On the other hand, the domestic stock market was engulfed by extreme fear during the previous trading session, staging a record-breaking market crash. The KOSPI plummeted 5.96% to close at 5,251.87, triggering the eighth circuit breaker in history, and the KOSDAQ also dropped 4.54%, triggering a sell sidecar, plunging the entire market into a state of paralysis. Foreign and institutional investors dumped a combined total of 4.6 trillion won in volume, and top market-cap semiconductor stocks including Samsung Electronics and SK Hynix were pushed down by 7.8% to a maximum of 10.8%, driving the index decline. Today's market is expected to unfold a recovery phase, reversing the previous day's excessive panic selling, inheriting the rebound of the New York stock market and the downward stabilization of the exchange rate.

Key Industry Issues and Insights

The semiconductor sector is in a situation where extreme fear and strong fundamentals collide. Although domestic bellwethers took a direct hit from foreign panic selling, concerns over the industry were partially dispelled as Nvidia (NASDAQ: NVDA) (+2.7%), AMD (NASDAQ: AMD) (+5.3%), and SanDisk (NASDAQ: SNDK) (+11.64%) all rebounded simultaneously in the US market. In particular, Wonik IPS is certain to benefit from the expansion of memory equipment investments by Samsung Electronics and SK Hynix, with analysis indicating that its operating profit in 2026 will grow by 199% year-on-year. The target price has been revised upward to 160,000 won, suggesting that despite short-term index volatility, earnings confidence in key equipment stocks remains solid.

In the pharmaceutical and bio sector, fortunes are starkly divided depending on the success or failure of clinical trials for individual stocks. Xenon Pharmaceuticals (NASDAQ: XENE), which succeeded in Phase 3 clinical trials for its epilepsy treatment, saw a record surge of 49.64%, while Roche, which failed its breast cancer treatment clinical trial, exacerbated volatility by falling 7% intraday. Domestically, Celltrion continues its global territorial expansion by obtaining approval for its 'Eylea' biosimilar from Mexican authorities. Furthermore, the actions of Eli Lilly (NYSE: LLY), which signed an investment memorandum of understanding worth 750 billion won with the Ministry of Health and Welfare, are highly likely to act as a catalyst to accelerate the qualitative growth of the domestic bio ecosystem.

The energy and raw materials markets continue to see a thematic market due to the aftermath of the Middle East conflict. Concerns over fertilizer supply disruptions led to surges in Namhae Chemical(+17.5%) and Chobi (+11.9%), while SK Gas, which is expected to benefit from rising energy prices, also showed strength, rising by 9.1%. In the case of the automotive industry, despite the burden of oil prices and exchange rates, it is noteworthy that Sang-A Frontec has set out to strengthen its next-generation mobility competitiveness by recruiting former Hyundai Motor Vice President Kim Sae-hoon, a hydrogen expert.

Market Signals

• Circuit Breakers and Undervalued Territory: The KOSPI plummeted 5.96%, falling to a 12-month forward price-to-earnings ratio (PER) level of 8.4 times. Excluding the financial crisis, this corresponds to a historically bottom area, making its entry into a technical oversold zone certain.

• Extreme Volatility in the Bio Sector: Xenon Pharmaceuticals (NASDAQ: XENE), which announced the success of its Phase 3 clinical trials for epilepsy, skyrocketed by 49.64%, proving that the growth momentum within the sector remains valid. The success or failure of new drug pipelines is the key variable reshaping corporate value.

• Mitigation of Exchange Rate and Energy Risks: The won-dollar exchange rate, which soared to 1,495.4 won intraday, has fallen to 1,460.6 won in the offshore non-deliverable forward (NDF) market, with volatility subsiding. Synchronized with the regression of WTI crude prices, it is serving as a psychological resistance line for the market.

Epoch View: Investment Implications

The triggering of the index's circuit breaker marks the peak of fear and, paradoxically, signifies an attractive entry point from a value investing perspective. The current corporate valuation of the KOSPI is at a level that excessively reflects macroeconomic uncertainties, and the semiconductor-led rebound in the New York stock market is a core driver that will secure downward rigidity for the domestic stock market.

In the short term, it is necessary to monitor the trends of energy price volatility and Middle East geopolitical risks, but a selective approach centered on semiconductor equipment stocks with secured earnings visibility and biosimilar stocks that have obtained global approvals is essential. In particular, as this is a time when the return of foreign investors is expected alongside exchange rate stability, a split purchase strategy for excessively oversold large-cap stocks is a rational choice.

This content was written through News Epoch's proprietary AI algorithm, which tracks and analyzes public data from research centers of major domestic securities firms in real-time. It is an objective summary based on collected data, and it is clarified that it is not a solicitation or recommendation for investment in specific stocks.